Get started
Author

Michael Burkard

Observed names: Burkard Michael R., Burkard, Michael R., M R Burkard, M. R. BURKARD, Michael R Burkard, Michael R. Burkard
OpenAlex ID: A5046487180
The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
2019 · Jill Hallin, Lars D. Engstrom, et al. · Cancer Discovery · 1,283
Identification of the Clinical Development Candidate MRTX849 , a Covalent KRASG12C Inhibitor for the Treatment of Cancer
2020 · Jay B. Fell, John P. Fischer, et al. · Journal of Medicinal Chemistry · 616
Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development
2016 · James F. Blake, Michael Burkard, et al. · Journal of Medicinal Chemistry · 155
PDF
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity
2018 · Jay B. Fell, John P. Fischer, et al. · ACS Medicinal Chemistry Letters · 111
Spirocyclic β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors: From Hit to Lowering of Cerebrospinal Fluid (CSF) Amyloid β in a Higher Species
2013 · Kevin W. Hunt, Adam W. Cook, et al. · Journal of Medicinal Chemistry · 59
Discovery of Highly Potent, Selective, and Efficacious Small Molecule Inhibitors of ERK1/2
2015 · Li Ren, Jonas Grina, et al. · Journal of Medicinal Chemistry · 44
Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2
2014 · James F. Blake, John J. Gaudino, et al. · Bioorganic & Medicinal Chemistry Letters · 38
Discovery of 7-Tetrahydropyran-2-yl Chromans: β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors That Reduce Amyloid β-Protein (Aβ) in the Central Nervous System
2014 · Allen A. Thomas, Kevin W. Hunt, et al. · Journal of Medicinal Chemistry · 38
Emergence and Targeting of Acquired and Hereditary Resistance to Multikinase RET Inhibition in Patients With RET-Altered Cancer
2019 · Lori J. Wirth, Takashi Kohno, et al. · JCO Precision Oncology · 36
Transient reexpression of an embryonic autonomous growth phenotype by adult carotid artery smooth muscle cells after vascular injury
2000 · Mary C.M. Weiser-Evans, Bryan E. Quinn, et al. · Journal of Cellular Physiology · 34
Rationally designed non-peptides: Variously substituted piperazine libraries for the discovery of bradykinin antagonists and other G-protein-coupled receptor ligands
1996 · Val S. Goodfellow, Chris P. Laudeman, et al. · Molecular Diversity · 30
Bradykinin Receptor Antagonists Containing N-Substituted Amino Acids: In Vitro and in Vivo B2 and B1 Receptor Antagonist Activity
1996 · Val S. Goodfellow, Manoj V. Marathe, et al. · Journal of Medicinal Chemistry · 29
Comparative profile of novel potent bradykinin antagonists at human B1 and B2 receptors
1996 · Michael Burkard, John S. Zuzack, et al. · Immunopharmacology · 25
New bradykinin antagonists having very high potency at B1 receptors
1996 · Lajos Gera, John M. Stewart, et al. · Immunopharmacology · 24
8-Tetrahydropyran-2-yl Chromans: Highly Selective Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors
2014 · Allen A. Thomas, Kevin W. Hunt, et al. · Journal of Medicinal Chemistry · 19
A new class of potent bradykinin antagonist dimers
1996 · Lajos Gera, John M. Stewart, et al. · Immunopharmacology · 17
Abstract DDT02-03: Discovery of GDC-0994, a potent and selective ERK1/2 inhibitor in early clinical development
2014 · Kirk Robarge, Jacob Schwarz, et al. · Cancer Research · 15
A conformationally restrained series of AT1-selective angiotensin II antagonists
1994 · Philip A. Carpino, Scott F. Sneddon, et al. · Bioorganic & Medicinal Chemistry Letters · 13
Synthesis, characterization, and PK/PD studies of a series of spirocyclic pyranochromene BACE1 inhibitors
2014 · Matthew Volgraf, Lina Chan, et al. · Bioorganic & Medicinal Chemistry Letters · 12
Abstract B192: Identification and characterization of highly potent and selective RET kinase inhibitors for the treatment of RET-driven cancers
2015 · Barbara J. Brandhuber, Nisha Nanda, et al. · Molecular Cancer Therapeutics · 7
Elvn-001, a Next Generation ATP-Competitive ABL1 Tyrosine Kinase Inhibitor for the Treatment of Chronic Myeloid Leukemia
2022 · Stefan D Gross, Christopher A. Eide, et al. · Blood · 5
Inducible bradykinin B 1 receptor in isolated human ileum
1996 · John S. Zuzack, Michael R. Burkard, et al. · Immunopharmacology · 5
Dihydropyridines: a new class of angiotensin II antagonists
1994 · Ronald T. Wester, Christian J. Mularski, et al. · Bioorganic & Medicinal Chemistry Letters · 5
Bradykinin antagonists in human systems: Correlation between receptor binding, calcium signalling in isolated cells, and functional activity in isolated ileum
1997 · Maciej Wieczorek, Anna Pilyavskaya, et al. · Biochemical Pharmacology · 4
Abstract 5515: ELVN-001, a highly selective ATP-competitive ABL1 tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia alone or in combination with asciminib
2025 · Stefan David Gross, Christopher A. Eide, et al. · Cancer Research · 1
Works count: 43
Citation count: 2,625
H-index: 16
I10-index: 19
Year
Topic
Type